comparemela.com

Latest Breaking News On - Nmet rckt us77313f1066 - Page 1 : comparemela.com

Rocket Pharmaceuticals Receives FDA Fast Track and Orphan Drug Designations for RP-A601 Gene Therapy for PKP2 Arrhythmogenic Cardiomyopathy

CRANBURY - Rocket Pharmaceuticals, Inc. , a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need,. | June 9, 2023

Kevin giordanoDrug administrationRocket pharmaceuticals incFast trackOrphan drugInvestigational new drugRolling reviewBiologic license applicationArrhythmogenic cardiomyopathyFanconi anemiaLeukocyte adhesion deficiency iPyruvate kinase deficiencyDanon diseasePrivate securities litigation reform actRisk factorAnnual report

Rocket Pharmaceuticals Receives European Medicines Agency (EMA) Priority Medicines (PRIME) Designation for RP-A501 Gene Therapy for Danon Disease

Rocket Pharmaceuticals, Inc. , a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today. | May 31, 2023

Kinnari patelRocket pharmaceuticals incEuropean medicines agencyYork heart associationRocket pharmaceuticalsPriority medicinesDanon diseaseRegenerative medicine advanced therapyFast trackOrphan drugRare pediatricChief operating officerEuropean regulatoryNew york heart associationKansas city cardiomyopathyFanconi anemia

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-L301 Gene Therapy for Pyruvate Kinase Deficiency (PKD)

Rocket Pharmaceuticals, Inc. , a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today. | May 23, 2023

United statesInvestigaciones energKinnari patelEnfermedades rarasMedioambientalesy tecnolRocket pharmaceuticals incDrug administrationMeeting of the american society geneRocket pharmaceuticalsRegenerative medicine advanced therapyPyruvate kinase deficiencyChief operating officerCentury cures actBreakthrough therapyFast trackOrphan drug

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease

Rocket Pharmaceuticals, Inc. , a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today. | February 7, 2023

Gaurav shahYork heart associationDrug administrationRocket pharmaceuticals incRocket pharmaceuticalsRegenerative medicine advanced therapyDanon diseaseChief executive officerCentury cures actBreakthrough therapyBiologics license applicationOrphan drugRare pediatricNew york heart associationKansas city cardiomyopathy questionnaireFanconi anemia

vimarsana © 2020. All Rights Reserved.